Logo image of GLPG

GALAPAGOS NV-SPON ADR (GLPG) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:GLPG - US36315X1019 - ADR

32.33 USD
+0.7 (+2.21%)
Last: 12/10/2025, 4:30:01 PM
32.33 USD
0 (0%)
After Hours: 12/10/2025, 4:30:01 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to GLPG. GLPG was compared to 531 industry peers in the Biotechnology industry. The financial health of GLPG is average, but there are quite some concerns on its profitability. GLPG is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year GLPG has reported negative net income.
In the past year GLPG has reported a negative cash flow from operations.
In multiple years GLPG reported negative net income over the last 5 years.
GLPG had a negative operating cash flow in each of the past 5 years.
GLPG Yearly Net Income VS EBIT VS OCF VS FCFGLPG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B

1.2 Ratios

GLPG has a better Return On Assets (-12.41%) than 82.30% of its industry peers.
GLPG has a better Return On Equity (-17.82%) than 84.56% of its industry peers.
Industry RankSector Rank
ROA -12.41%
ROE -17.82%
ROIC N/A
ROA(3y)0.68%
ROA(5y)-1.06%
ROE(3y)0.5%
ROE(5y)-2.77%
ROIC(3y)N/A
ROIC(5y)N/A
GLPG Yearly ROA, ROE, ROICGLPG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10 -20 -30

1.3 Margins

In the last couple of years the Profit Margin of GLPG has grown nicely.
Looking at the Gross Margin, with a value of 84.25%, GLPG belongs to the top of the industry, outperforming 86.82% of the companies in the same industry.
GLPG's Gross Margin has declined in the last couple of years.
GLPG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y9.68%
GM growth 3Y-4.31%
GM growth 5YN/A
GLPG Yearly Profit, Operating, Gross MarginsGLPG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100

More info and screens

4

2. Health

2.1 Basic Checks

GLPG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GLPG remains at a similar level compared to 1 year ago.
Compared to 5 years ago, GLPG has more shares outstanding
The debt/assets ratio for GLPG is higher compared to a year ago.
GLPG Yearly Shares OutstandingGLPG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
GLPG Yearly Total Debt VS Total AssetsGLPG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

GLPG has an Altman-Z score of 1.51. This is a bad value and indicates that GLPG is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of GLPG (1.51) is better than 63.47% of its industry peers.
GLPG has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.00, GLPG perfoms like the industry average, outperforming 47.83% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.51
ROIC/WACCN/A
WACC7.82%
GLPG Yearly LT Debt VS Equity VS FCFGLPG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

2.3 Liquidity

A Current Ratio of 8.62 indicates that GLPG has no problem at all paying its short term obligations.
GLPG has a Current ratio of 8.62. This is in the better half of the industry: GLPG outperforms 76.08% of its industry peers.
A Quick Ratio of 8.55 indicates that GLPG has no problem at all paying its short term obligations.
With a decent Quick ratio value of 8.55, GLPG is doing good in the industry, outperforming 76.27% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.62
Quick Ratio 8.55
GLPG Yearly Current Assets VS Current LiabilitesGLPG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

More info and screens

1

3. Growth

3.1 Past

GLPG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -311.50%.
The earnings per share for GLPG have been decreasing by -12.47% on average. This is quite bad
Looking at the last year, GLPG shows a very negative growth in Revenue. The Revenue has decreased by -43.08% in the last year.
Measured over the past years, GLPG shows a very negative growth in Revenue. The Revenue has been decreasing by -20.82% on average per year.
EPS 1Y (TTM)-311.5%
EPS 3YN/A
EPS 5Y-12.47%
EPS Q2Q%-298.7%
Revenue 1Y (TTM)-43.08%
Revenue growth 3Y-20.01%
Revenue growth 5Y-20.82%
Sales Q2Q%18.9%

3.2 Future

GLPG is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -40.75% yearly.
The Revenue is expected to decrease by -7.07% on average over the next years.
EPS Next Y-541.12%
EPS Next 2Y-90.61%
EPS Next 3Y-66.3%
EPS Next 5Y-40.75%
Revenue Next Year-3.68%
Revenue Next 2Y-2.5%
Revenue Next 3Y-3.52%
Revenue Next 5Y-7.07%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
GLPG Yearly Revenue VS EstimatesGLPG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
GLPG Yearly EPS VS EstimatesGLPG Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GLPG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GLPG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GLPG Price Earnings VS Forward Price EarningsGLPG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GLPG Per share dataGLPG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

GLPG's earnings are expected to decrease with -66.30% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-90.61%
EPS Next 3Y-66.3%

More info and screens

0

5. Dividend

5.1 Amount

GLPG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GALAPAGOS NV-SPON ADR

NASDAQ:GLPG (12/10/2025, 4:30:01 PM)

After market: 32.33 0 (0%)

32.33

+0.7 (+2.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)02-24 2026-02-24/amc
Inst Owners24.89%
Inst Owner Change-0.7%
Ins Owners0%
Ins Owner ChangeN/A
Market Cap2.13B
Revenue(TTM)286.76M
Net Income(TTM)-436.00M
Analysts51.58
Price Target34.5 (6.71%)
Short Float %2.03%
Short Ratio4.97
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-10823.9%
Min EPS beat(2)-19965.4%
Max EPS beat(2)-1682.53%
EPS beat(4)1
Avg EPS beat(4)-5642.06%
Min EPS beat(4)-19965.4%
Max EPS beat(4)154.1%
EPS beat(8)4
Avg EPS beat(8)-2655.53%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-6.56%
Min Revenue beat(2)-10.27%
Max Revenue beat(2)-2.86%
Revenue beat(4)1
Avg Revenue beat(4)-5.15%
Min Revenue beat(4)-11.82%
Max Revenue beat(4)4.35%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.35%
PT rev (3m)0.6%
EPS NQ rev (1m)55.59%
EPS NQ rev (3m)55.59%
EPS NY rev (1m)-79.05%
EPS NY rev (3m)-79.05%
Revenue NQ rev (1m)0.15%
Revenue NQ rev (3m)0.15%
Revenue NY rev (1m)1.81%
Revenue NY rev (3m)4.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.38
P/FCF N/A
P/OCF N/A
P/B 0.75
P/tB 0.75
EV/EBITDA N/A
EPS(TTM)-7.72
EYN/A
EPS(NY)-2.13
Fwd EYN/A
FCF(TTM)-5.07
FCFYN/A
OCF(TTM)-4.75
OCFYN/A
SpS5.06
BVpS43.21
TBVpS43.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -12.41%
ROE -17.82%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.25%
FCFM N/A
ROA(3y)0.68%
ROA(5y)-1.06%
ROE(3y)0.5%
ROE(5y)-2.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y9.68%
GM growth 3Y-4.31%
GM growth 5YN/A
F-Score2
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40%
Cap/Sales 6.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.62
Quick Ratio 8.55
Altman-Z 1.51
F-Score2
WACC7.82%
ROIC/WACCN/A
Cap/Depr(3y)93.92%
Cap/Depr(5y)187.53%
Cap/Sales(3y)17%
Cap/Sales(5y)15.79%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-311.5%
EPS 3YN/A
EPS 5Y-12.47%
EPS Q2Q%-298.7%
EPS Next Y-541.12%
EPS Next 2Y-90.61%
EPS Next 3Y-66.3%
EPS Next 5Y-40.75%
Revenue 1Y (TTM)-43.08%
Revenue growth 3Y-20.01%
Revenue growth 5Y-20.82%
Sales Q2Q%18.9%
Revenue Next Year-3.68%
Revenue Next 2Y-2.5%
Revenue Next 3Y-3.52%
Revenue Next 5Y-7.07%
EBIT growth 1Y-67.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-68.33%
EBIT Next 3Y-15.45%
EBIT Next 5Y9.17%
FCF growth 1Y46.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y48.17%
OCF growth 3YN/A
OCF growth 5YN/A

GALAPAGOS NV-SPON ADR / GLPG FAQ

What is the fundamental rating for GLPG stock?

ChartMill assigns a fundamental rating of 2 / 10 to GLPG.


What is the valuation status of GALAPAGOS NV-SPON ADR (GLPG) stock?

ChartMill assigns a valuation rating of 0 / 10 to GALAPAGOS NV-SPON ADR (GLPG). This can be considered as Overvalued.


What is the profitability of GLPG stock?

GALAPAGOS NV-SPON ADR (GLPG) has a profitability rating of 3 / 10.


What is the financial health of GALAPAGOS NV-SPON ADR (GLPG) stock?

The financial health rating of GALAPAGOS NV-SPON ADR (GLPG) is 4 / 10.